
ILD Prevalence and Risk Factors Across Autoimmune Rheumatic Diseases
ILD prevalence varies widely across autoimmune diseases, and much depends on how carefully clinicians look. The panel reviews the data, the clinical clues, and the antibodies that signal elevated risk.
Episodes in this series
"ILD Prevalence and Risk Factors Across Autoimmune Rheumatic Diseases" takes up the question of how common ILD really is across the autoimmune rheumatic diseases.
Dr. Dikranian admits that no one knows the true prevalence, because the data are limited. He separates ILD in general from the smaller share of patients who develop progressive pulmonary fibrosis. Citing a large retrospective analysis covering millions of patients, he places ILD in a quarter to half of people with rheumatoid arthritis. About a fifth of those patients show progressive features. The figure approaches 75% in systemic sclerosis, while Sjögren's disease and mixed connective tissue disease fall between 25% and 75%. In his view, the main driver of these numbers is how well clinicians screen.
Dr. Hsu offers a different frame. In a room of 100 patients with autoimmune ILD, about half would have scleroderma and a quarter rheumatoid arthritis. The remaining quarter would include Sjögren's syndrome, mixed connective tissue disease, and undifferentiated connective tissue disease.
On risk, Dr. Dikranian calls stratification an evolving science. In rheumatoid arthritis, seropositivity, male sex, and current or past smoking predict more ILD, and seropositivity also raises risk in anti-synthetase syndrome. He screens newly diagnosed systemic sclerosis and anti-synthetase patients regardless of symptoms, but often reserves screening in rheumatoid arthritis for higher-risk or symptomatic patients.
Dr. Hsu starts with a careful history for muscle disease and an exam for rashes or skin thickening. She then turns to antibodies, noting that 70% of Scl-70-positive patients and 20% of anticentromere-positive patients can develop ILD. Seronegative Sjögren's patients with symptoms may need a lip biopsy to confirm the diagnosis. Dr. Dikranian adds that pulmonologists increasingly refer patients with interstitial pneumonia with autoimmune features. Dr. Hsu notes that these patients may have a high-titer ANA and few physical findings, yet still need treatment.
Up next, in "ILD Screening in Autoimmune Disease: HRCT, PFTs, and a Patient's Path," Dr. Dikranian walks through the right screening tests and how often to repeat them, and Betsy Taylor describes the long road to her own diagnosis.
Related to this article








